» Articles » PMID: 16213416

BiTEs: Bispecific Antibody Constructs with Unique Anti-tumor Activity

Overview
Specialty Pharmacology
Date 2005 Oct 11
PMID 16213416
Citations 116
Authors
Affiliations
Soon will be listed here.
Abstract

Bispecific T-cell engager molecules (BiTEs) constitute a class of bispecific single-chain antibodies for the polyclonal activation and redirection of cytotoxic T cells against pathogenic target cells. BiTEs combine a unique set of properties that have not yet been reported for any other kind of bispecific antibody construct, namely extraordinary potency and efficacy against target cells at low T-cell numbers without the need for T-cell co-stimulation. Here we review novel insights into the mechanism of BiTE action, which help to explain the unique features of BiTEs, as well as data from various animal models demonstrating the outstanding therapeutic potential of BiTEs for the treatment of malignant diseases.

Citing Articles

Bispecific FpFs: a versatile tool for preclinical antibody development.

Collins M, Ibeanu N, Grabowska W, Awwad S, Khaw P, Brocchini S RSC Chem Biol. 2024; .

PMID: 39347456 PMC: 11427889. DOI: 10.1039/d4cb00130c.


[Chinese consensus for the bispecific T cell engager in the treatment of acute lymphoblastic leukemia (2024)].

Zhonghua Xue Ye Xue Za Zhi. 2024; 45(7):629-636.

PMID: 39231766 PMC: 11388125. DOI: 10.3760/cma.j.cn121090-20240528-00194.


DARPin-fused T cell engager for adenovirus-mediated cancer therapy.

Freitag P, Kolibius J, Wieboldt R, Weber R, Hartmann K, van Gogh M Mol Ther Oncol. 2024; 32(3):200821.

PMID: 39021370 PMC: 11253662. DOI: 10.1016/j.omton.2024.200821.


Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future.

Lampe H, Tam L, Hansen A Front Pharmacol. 2024; 15:1399802.

PMID: 38873417 PMC: 11169794. DOI: 10.3389/fphar.2024.1399802.


Bispecific and multispecific antibodies in oncology: opportunities and challenges.

Goebeler M, Stuhler G, Bargou R Nat Rev Clin Oncol. 2024; 21(7):539-560.

PMID: 38822215 DOI: 10.1038/s41571-024-00905-y.